RxDoctor Payments Data

William Lutes, DO

Adult Reconstructive Orthopaedic Surgery · Kenosha, WINPI 1437123080

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.1%), speaking fees and royalties or licence payments — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 76.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $231,706 and has fallen 52.8% since, to $109,412 in 2025.

$1,024,543in general payments, 2019–2025

Across 998 payments — averaging $1026.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$779K
  • Orthalign Inc$242K
  • Globus Medical$2K
  • Encore Medical, LP$1K
  • Linkbio Corp$271
  • Stryker$142
  • plus $422 from 5 others
$265in research payments, 2019–2025

Across 1 payment — averaging $265.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$265
$283,517in ownership & investment interests, 2019–2025

Across 6 payments — averaging $47,253 each. An ownership or investment interest held by the physician or an immediate family member.

  • Orthalign Inc$284K

What the payments were for

  • Royalty or licence$160,31416%
  • Consulting fees$370,22636%
  • Speaking & faculty fees$335,34733%
  • Travel & lodging$139,68414%
  • Food & beverage$18,9382%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$119,048
Medicare patients
188
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mupirocin70$388
Prednisone18$92

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →